文献速递介入腹部CTMRUS

不可逆电穿孔治疗肝脏恶性肿瘤的疗效与安全性:系统综述与Meta分析

Efficacy and safety of irreversible electroporation for malignant liver tumors: a systematic review and meta-analysis.
PubMed 文献 · Eur Radiol · 2021-02-27

该系统综述与Meta分析纳入25项研究共776例肝脏恶性肿瘤患者,评估不可逆电穿孔(IRE)的生存获益与并发症。汇总6、12、24、36个月总生存率分别为93.28%、81.29%、61.47%、40.88%,总并发症率23.7%,主要并发症(SIR C-F级)占6.9%。作者结论认为IRE与良好的总生存和无进展生存相关,虽然总并发症率较高,但多数为轻微并发症。

要点

  • IRE治疗后汇总6、12、24个月总生存率分别为93.28%、81.29%、61.47%,36个月为40.88%。
  • 汇总6、12、24个月无进展生存率分别为79.72%、64.19%、49.05%。
  • 总并发症率23.7%,主要并发症(SIR C-F级)占6.9%,多数为轻微并发症。

诊断标准与关键数值

  • 汇总总生存率:6个月93.28%(95%CI 63.23-99.12,I²=67%),12个月81.29%(95%CI 69.80-89.22,I²=73%),24个月61.47%(95%CI 52.81-69.46,I²=0%),36个月40.88%(95%CI 28.43-54.61,I²=64%)。
  • 汇总无进展生存率:6个月79.72%(95%CI 67.88-87.97,I²=70%),12个月64.19%(95%CI 56.68-71.06,I²=57%),24个月49.05%(95%CI 11.47-87.73,I²=96%)。
  • 并发症按介入放射学会(SIR)分类分级:总并发症率23.7%,主要并发症(C-F级)占6.9%。
  • 转移瘤、肝细胞癌和胆管癌患者分别为354例、285例和100例。

临床应用与阅片要点

  • 作者结论认为IRE与良好的总生存和无进展生存相关,总并发症率虽高但多数为轻微并发症。
  • 肝细胞癌在12个月和36个月总生存方面表现更好。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The data regarding overall survival (OS) and progression-free survival (PFS) following irreversible electroporation (IRE) is scarce. We performed a systematic review of the safety and efficacy of IRE for liver malignancies.

METHODS: Searches of MEDLINE, EMBASE, and SCOPUS databases were performed through September 1, 2019. Studies reporting the survival data (OS and PFS) and complications (graded according to the Society of interventional Radiology classification) were included. A generalized linear mixed method with a random-effects model was used for assessing pooled incidence rates and corresponding 95% confidence intervals (CIs).

RESULTS: A total of 25 studies (n = 776, 15 prospective, 10 retrospective) were included. Metastasis, hepatocellular carcinoma, and cholangiocarcinoma were present in 354, 285, and 100 patients, respectively. The pooled OS at 6, 12, 24, and 36 months was 93.28% (95% CI: 63.23-99.12, I2= 67%), 81.29% (95% CI: 69.80-89.22, I2 = 73%), 61.47% (95% CI: 52.81-69.46, I2 = 0%), and 40.88% (95% CI: 28.43-54.61, I2 = 64%), respectively. The pooled PFS at 6, 12, and 24 months was 79.72% (95% CI: 67.88-87.97, I2 = 70%), 64.19% (95% CI: 56.68-71.06, I2 = 57%), 49.05% (95% CI: 11.47-87.73, I2 = 96%), respectively. Overall complication rate was 23.7%. Major complications (grade C-F) occurred in 6.9% patients.

CONCLUSION: IRE is associated with favorable OS and PFS. Although the overall complication rate is high, most complications are graded as minor.

KEY POINTS: • The pooled OS and PFS at 6, 12, and 24 months for all the tumor types was 93.28% and 79.72%, 81.29% and 64.19%, and 61.47% and 49.05%, respectively. • HCC was associated with a better OS at 12 and 36 months. • The overall complication rate was 23.7%, with major complications (SIR grade C-F) comprising 6.9%.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Gupta P, Maralakunte M, Sagar S, et al. Efficacy and safety of irreversible electroporation for malignant liver tumors: a systematic review and meta-analysis. Eur Radiol. 2021. PMID: 33638687. doi:10.1007/s00330-021-07742-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。